Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 16/20 | 0.66 |
| ▸ | CCND1 | P24385 | 14/20 | 0.66 |
| ▸ | CCND2 | P30279 | 13/20 | 0.66 |
| ▸ | CCND3 | P30281 | 13/20 | 0.66 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.64 |
| ▸ | CDK2 | P24941 | 7/20 | 0.64 |
| ▸ | CCNE2 | O96020 | 6/20 | 0.64 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.64 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.64 |
| ▸ | PAK4 | O96013 | 1/20 | 0.64 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.64 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.64 |
| ▸ | FGFR4 | P22455 | 6/20 | 0.63 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.63 |
| ▸ | CDK1 | P06493 | 4/20 | 0.63 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.63 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.63 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.63 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.63 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10192643 | 0.89 | CDK4 (0.68) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL5264295 | 0.85 | CDK4 (0.72) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL16285712 | 0.83 | CDK4 (0.43) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL10192642 | 0.81 | CDK4 (0.60) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL5267657 | 0.80 | CDK4 (0.70) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL10192628 | 0.80 | CDK4 (0.70) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL10192625 | 0.80 | CDK4 (0.70) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL5265884 | 0.80 | CDK4 (0.78) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL5264325 | 0.80 | CDK4 (1.00) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL5318362 | 0.80 | CDK4 (0.78) | CDK4CCND1CCND2CCND3CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130231348-A1 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | AFRAXIS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | AFRAXIS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | AFRAXIS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2011090666-A2 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011090666-A2 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011063415-A2 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | AFRAXIS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011063415-A2 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | AFRAXIS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011044537-A2 | METHODS FOR TREATING ALZHEIMER'S DISEASE | AFRAXIS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011044537-A2 | METHODS FOR TREATING ALZHEIMER'S DISEASE | AFRAXIS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011009097-A2 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011009097-A2 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2010071846-A2 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010071846-A2 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | GRIN2A, GRIN2C, GRIN3A | CDK4 2824/4885CCND1 4822/4885CCND2 4718/4885 |
| US-20130231348-A1 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK3, PAK5 | CDK4 408/4885CCND1 3984/4885CCND2 3905/4885 |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | SMN1; SMN2, PYGB, PMP22 | CDK4 2822/4885CCND1 4884/4885CCND2 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.